Originally published on November 4, 2014
Most investors don’t realize that the average stock fluctuates by 50% in any given year from its low to its high. If you’ve properly estimated a stock’s value and you’re patient, there should be more than enough opportunities to buy fundamentally strong companies at attractive valuations…which is the key to long-term success in the stock market. In this post, I am going to demonstrate how a relative value analysis is conducted on a publicly traded company. To do so, I’m going to use three separate case studies: 21st Century Fox (NASDAQ:FOXA), HCA Holdings (NYSE:HCA), and Abbott Labs (NYSE:ABT).
21st Century Fox
21st Century Fox is a diversified international media and entertainment company with a number of high growth businesses. The company’s operating segments include Filmed Entertainment (20th Century Fox), TV (FOX Broadcast Network), Cable Networks (Fox News Channel, FX) and Direct Broadcast Satellite TV (Sky Italia, Sky Deutscheland). The company also has significant equity investments in direct-to-home satellite TV provider British Sky Broadcast. I recommended FOXA in July 2014. As part of my recommendation, I included a comparable company analysis; see the figure below.
21st Century Fox traded at a modest premium to its peers in July. Using next twelve months' P/E, the company was trading at 19.7x earnings vs. the group average of 18.7x despite having a much higher expected EPS growth rate (25.7% vs. 14.6% for the group). Similarly, the stock traded at 12x EBITDA vs. 10.7x for the group despite having forecasted EBITDA growth of 16.8% vs. only 7.7% for the group. As noted in Part 2 of this series, companies with similar multiples should have similar growth rates. Given FOXA’s much higher growth rate, this comparative analysis indicates that there is room for multiple expansion relative to the peer group as investors better understand (and appreciate) the company’s growth profile.
In April 2014, I recommended a position in HCA Holdings. HCA is the largest hospital player in the U.S. At the time, there were a lot of moving parts (e.g., changes in reimbursement model). Because of this uncertainty, my near-term estimates were conservative and below consensus. Longer-term, my estimates were above consensus reflecting the positive effects of Obamacare on utilization and bad debt expense. Provided below is an excerpt from that report.
My 2014-2017 EPS estimates are $3.65 (consensus: $3.69), $4.50 (consensus: $4.32), $5.10 (consensus: $4.90), and $5.70 (consensus: NA), respectively. My secular earnings growth estimate is +13%, which is comprised of +6% revenue growth, +2% operating margin contribution, and +5% from capital deployment.
- Revs (+6%) – Revs should increase by +6% over the next several years driven by a combination of higher patient revenue and lower bad debt expense
- Operating Margin (+2%) – HCA’s average market share by state of 12% is nearly double its nearest competitor at 7%, driving superior asset returns with EBITDA margins of ~19% vs. peers at ~12%. That said, with already high margins I am only expecting improvement in margins to contribute +2% to annual EPS growth.
- Capital Deployment (+5%) – With solid FCF, the announcement of a new stock repurchase program following incremental debt retirement in 2H14 seems increasingly likely. 2013 OCF was $3.7B with FCF of $1.7B (7% of market cap). The previous repurchase was completed in 4Q13. HCA recently announced refinancing of some of its notes. After these notes are refinanced, HCA can redo its covenants to allow for a bigger share repurchase and/or a special dividend.
The stock currently trades at a P/E of 13.3x my 2014 estimate and 11.5x my 2015 estimate. This equates to a relative multiple of 0.86x. My valuation estimate of $59 price target reflects a fair value multiple of 1.05x, which better reflects the anticipated +13% earnings growth from the implementation of the Affordable Care Act (ACA). The $59 target represents 8.4x 2014 EBITDA, near the midpoint of its historical 6-10x multiple range when HCA was previously public. Upside to my estimate would be driven by a greater-than-expected benefit to EBITDA from healthcare reform. Downside would come from weak hospital utilization and/or less reduction in bad debt expense from ACA. The company does not pay a dividend.
I compared my price target to that of the sell-side analysts following the stock. At the time, the median PT for the Street was $57 (+17% upside). The median PT for the best analysts was $60 (+23% upside). I define “best” as those analysts ranked first, second, or third in Institutional Investor’s annual survey. My $59 estimate implies ~21% upside in the stock. If hospital utilization increases (and bad debt expense decreases) meaningfully from the Affordable Care Act, my PT may prove conservative.
Abbott Labs is a diversified global healthcare company with products in five categories: Pharmaceuticals (57% of revenues), Nutritionals (16%), Diagnostics (11%), Vascular (9%), and Diabetes Care (5%). The company generated $35.2 billion in sales in 2010. The geographic mix was 43% U.S. and 57% outside the U.S. Some of the company’s well known brands include: 1) HUMIRA, the leading biologic for the treatment of Rheumatoid Arthritis, 2) infant and adult nutritionals such as Similac and Ensure, 3) the coronary stent, XIENCE, and 4) the FreeStyle family of blood glucose monitoring systems for diabetics.
Source: FactSet Estimates and Interactive Data Corp via FactSet
The figure above reflects the quarterly P/E ratio from 2006-2011. The blue bars in the figure illustrate the P/E range in each quarter. In the second quarter of 2006), the stock traded at a P/E multiple that ranged from 15.9x to 17.6x. The black line that bisects the blue bar is the average multiple for that quarter (16.8x in 2Q06), and the red line that bisects the entire graph reflects the average multiple for the entire period (15.75x for the 5-year period depicted). These graphs can sometimes be used to identify inflection points in the stock meriting action.
From the figure, we can see that the peak and trough multiples over the 5-year period were 21.4x and 10.1x, respectively. In January 2011, the stock is trading at 10.3x, which is near its trough multiple. What is particularly noteworthy is that Abbott’s P/E multiple didn’t even reach this low in 2008 amidst the financial crisis. This suggests that either the stock is historically undervalued, or something has changed, either at Abbott or in the pharmaceutical industry, to suggest that the stock will be in a new era of lower P/E ratios. To get an idea, let’s look at the consensus growth rate for the company. Given that Wall Street analysts are forecasting double digit earnings growth for the next several years and the company has the free cash flow to support the 3.7% dividend yield, I’m inclined to believe the stock is historically undervalued.
We can use the 5-year P/E range to approximate the upside and downside on the stock. Using the peak multiple of 21.4x and the 2011 EPS estimate of $4.58, the stock could reach as high as $98 per share.
Expected Stock Price Using Peak Multiple = 2011 EPS Est. x Peak P/E = $4.58 x 21.4x = $98.01
With the stock currently at $46.95, the upside to $98 would represent a 108% return. On the other hand, the trough multiple of 10.1x implies downside risk of 2% to $46.25.
Expected Stock Price Using Trough Multiple = 2011 EPS Est. x Trough P/E = $4.58 x 10.1x = $46.25
Looking at a potential upside gain of 108% and a likely downside risk of only 2% (an upside/downside ratio of 54:1), the stock looks very attractive based on the 5-year P/E range. However, this upside/downside rate seems unrealistic; for context, a range of 3:1 or 4:1 is what many investors look for when picking stocks. Looking again at Figure 19.12, the P/E trend has been declining for over three years suggesting that it may be a secular trend to a sustainably lower P/E range, not a rotational move. However, since no reason for a sustained lower P/E stands out in terms of company growth prospects, cash flow, or dividend sustainability, it is reasonable to assume that rotation is the major factor driving the lower multiple. Even so, it may be more appropriate to use the stock’s 5-year average multiple of 15.75x, rather than its prior peak of 21.4x when estimating potential upside.
Expected Stock Price Using Average Multiple = 2011 EPS Est. x Average P/E = $4.58 x 15.75x = $72.13
If Abbott’s stock can regain it average multiple of 15.75x, the stock would trade at $72. With the stock currently at $46.95, there is 53% upside to $72. For downside risk, we have no historical P/Es to guide us. In a situation like this, I make the assumption that the stock has 10% downside risk. From $46.95, 10% downside would be $42.25. With the current annualized dividend of $1.82, and the assumed $42.25 price, that would produce a yield of 4.3%, a compelling level for a company with Abbott’s cash flow and growth prospects. Using the average multiple (rather than the peak multiple) and the 10% downside assumption, (rather than the trough multiple), the upside/downside ratio would be 5:1 (53% upside divided by 10% downside), which is very attractive (particularly when combined with the 3.7% yield). Even if we assumed the stock had 20% downside to $37.56 (producing a very compelling 4.8% dividend yield) the upside/downside ratio would still be favorable at 2.7:1.
Given these dynamics, I recommended ABT in January 2011 when the stock was under pressure.
Part 4 is dedicated to absolute value techniques; specifically, I discuss the theory behind them and walk through a hypothetical example. Finally, in Part 5, I apply those techniques to a publicly traded company.
Disclosure: This post is for informational and educational purposes only and shall not be construed to constitute investment advice. Nothing contained herein shall constitute a solicitation, recommendation, or endorsement to buy or sell 21st Century Fox stock (FOXA), HCA Holdings stock (HCA), Abbott Labs stock (ABT), or any other security. While the author does not hold a position of employment, directorship, or consultancy with the subject company, he and/or others he advises may hold a material investment in the subject company. The presentation contains and is based upon information that the author believes to be correct, but he has not verified that information and assumes no liability if such information is incorrect. No one should rely on the information contained in this presentation to make any investment decision. Before investing in 21st Century Fox stock (FOXA), HCA Holdings stock (HCA), Abbott Labs stock (ABT), or any other security, seek the advice of a qualified investment professional.